The Biomarkers, Symptoms, and Treatment of Multiple Sclerosis
A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neurodegenerative Diseases".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 92
Special Issue Editor
Interests: multiple sclerosis; amyotrophic lateral sclerosis; neuromyelitis optica; cefalalgia; neuro-ophthalmology; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multiple sclerosis (MS) is a persistent autoimmune neurodegenerative condition marked by an intricate clinical progression involving inflammation, demyelination, and axonal degeneration. Assessing relapse rates, disability progression, and lesion load via MRI helps identify disease activity and treatment responses. However, the utilization of clinical and imaging biomarkers falls short in enabling individual characterization and prediction. Thus, blood and cerebrospinal fluid (CSF) biomarkers related to axonal and neuronal damage, glial dysfunction, demyelination, and inflammation have been explored as actionable indicators for MS, shedding light on this disease's underlying pathology. Nevertheless, the integration of molecular biomarkers into clinical practice is made challenging by the prolonged validation process and the considerable time required for their implementation.
The aim of the current Special Issue is to provide more insights into the use of several clinical, imaging, and molecular biomarkers for the diagnosis, prognosis, and treatment response in MS.
Authors are invited to submit original research articles and reviews that address a broad range of topics, including the validation of current MS biomarkers, the application of more advanced screening technologies (e.g., gene expression and autoantibody arrays, microRNAs, and circulating microvesicles/exosomes), and the discovery of potential molecular biomarkers derived from blood or CSF samples for monitoring the impact of MS treatment in a clinical setting.
Dr. Clara Grazia Chisari
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple sclerosis
- progression
- disease activity
- symptoms
- biomarkers
- blood
- cerebrospinal fluid
